Lupus & antiphospholipid syndrome
Initiation of belimumab with higher daily prednisolone is effective for rapid glucocorticoid reduction: A 96-week retrospective study
Main finding · Baseline factors for ≥50% GC reduction at 96 weeks (multivariate, with age and disease duration)Result — go to the resultOdds ratio 1.25 95% CI 1.00–1.56Authors' conclusion
Our study showed that a delay in belimumab initiation led to higher SLEDAI-2K score and difficulty in achieving a 50% GC reduction at 96 weeks.
Study context
- Population
- SLE patients receiving belimumab, Kakogawa Central City hospital, 2019–2023median daily prednisolone 5 mg
- Participants
- 47 patients
- Outcome
- Baseline factors associated with ≥50% GC reduction
- Follow-up
- 96 weeks
Methodological detailssingle-centre, univariate and multivariate logistic analyses
- Single-centre
- Univariate and multivariate logistic analyses
Main finding
As reported in the abstract
Baseline factors for ≥50% GC reduction at 96 weeks (multivariate, with age and disease duration)
Odds ratio
1.25
95% CI 1.00–1.56
P = 0.047
Higher daily GC dose at baseline
OR 1.25 (95% CI 1.00–1.56); P = 0.047
Observational data: associations, not effects.
Further findings
Clinical course over 96 weeks
- Serological indices, daily glucocorticoid (GC) dose and SLEDAI-2K significantly improved
- GC reduction rate and SLEDAI-2K negatively correlated with duration from onset or last flare to belimumab initiation
- Lupus nephritis (LN) associated with higher SLEDAI-2K at 96 weeks; baseline SLEDAI-2K ≥10 associated with significantly higher GC dose at 96 weeks
Original publication
Initiation of belimumab with higher daily prednisolone is effective for rapid glucocorticoid reduction: A 96-week retrospective study. Lupus. Published 21 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →